Key result
In patients receiving prasugrel after everolimus-eluting stent implantation, the prevalence of intrastent thrombi at 9 months did not differ between acute coronary syndrome and stable coronary artery disease, though platelet reactivity at intervention independently predicted thrombus formation.
Why the study?
The impact of antiplatelet drug effects on mid-term local arterial responses following PCI remains uncertain.
Does the platelet reactivity of prasugrel affect the mid-term prevalence of intrastent thrombi in patients with acute coronary syndrome versus stable coronary artery disease undergoing everolimus-eluting stent implantation?
Cohort (n=187)
Single-blind
Yes
Does the platelet reactivity of prasugrel affect the mid-term prevalence of intrastent thrombi in patients with acute coronary syndrome versus stable coronary artery disease undergoing everolimus-eluting stent implantation?
Answers are grounded in this paper and cite their sources.
Achieving adequate platelet inhibition with prasugrel at the time of stent implantation is associated with reduced mid-term intrastent thrombus formation, regardless of whether the patient presents with ACS or stable CAD.
BACKGROUND: The impact of antiplatelet drug effects on mid-term local arterial responses following percutaneous coronary intervention (PCI) remains uncertain. We evaluated the impact of the platelet reactivity of prasugrel on mid-term vascular healing between acute coronary syndrome (ACS) and stable coronary artery disease (CAD). METHODS AND RESULTS: reaction units (PRU) with the frequency of malapposed or uncovered struts and intrastent thrombi (IST). The incidence of abnormal mid-term OCT findings did not different between the ACS and CAD arms, regardless of clinical presentation, except that uncovered struts were more frequent in the ACS than CAD arm. PRU at PCI was significantly associated with the frequency of IST at follow-up, but not with uncovered and malapposed struts. PRU at PCI was the only independent predictor of IST detected at follow-up (odds ratio 1.009). CONCLUSIONS: In patients undergoing EES implantation and receiving prasugrel, achieving an adequate antiplatelet effect at the time of stent implantation may regulate thrombus formation throughout the follow-up period.
No takes yet. Share an insight, caveat, or question.
Toba et al. (2021) conducted a cohort in Acute Coronary Syndrome and Stable Coronary Artery Disease (n=187). Acute coronary syndrome vs. Stable coronary artery disease was evaluated on Prevalence of intrastent thrombi (IST) detected at the 9-month follow-up (p=0.862). In patients receiving prasugrel after everolimus-eluting stent implantation, the prevalence of intrastent thrombi at 9 months did not differ between acute coronary syndrome and stable coronary artery disease, though platelet reactivity at intervention independently predicted thrombus formation.
Synapse has enriched 10 related papers. Consider them for comparative context: